1. Home
  2. IMAB vs GLU Comparison

IMAB vs GLU Comparison

Compare IMAB & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMAB
  • GLU
  • Stock Information
  • Founded
  • IMAB 2014
  • GLU 2004
  • Country
  • IMAB United States
  • GLU United States
  • Employees
  • IMAB N/A
  • GLU N/A
  • Industry
  • IMAB Biotechnology: Pharmaceutical Preparations
  • GLU Finance/Investors Services
  • Sector
  • IMAB Health Care
  • GLU Finance
  • Exchange
  • IMAB Nasdaq
  • GLU Nasdaq
  • Market Cap
  • IMAB 87.2M
  • GLU 92.2M
  • IPO Year
  • IMAB 2020
  • GLU N/A
  • Fundamental
  • Price
  • IMAB $0.99
  • GLU $15.63
  • Analyst Decision
  • IMAB Strong Buy
  • GLU
  • Analyst Count
  • IMAB 3
  • GLU 0
  • Target Price
  • IMAB $8.00
  • GLU N/A
  • AVG Volume (30 Days)
  • IMAB 354.5K
  • GLU 12.4K
  • Earning Date
  • IMAB 03-13-2025
  • GLU 01-01-0001
  • Dividend Yield
  • IMAB N/A
  • GLU 8.60%
  • EPS Growth
  • IMAB N/A
  • GLU N/A
  • EPS
  • IMAB N/A
  • GLU 0.62
  • Revenue
  • IMAB $3,313,984.00
  • GLU N/A
  • Revenue This Year
  • IMAB N/A
  • GLU N/A
  • Revenue Next Year
  • IMAB N/A
  • GLU N/A
  • P/E Ratio
  • IMAB N/A
  • GLU $22.50
  • Revenue Growth
  • IMAB N/A
  • GLU N/A
  • 52 Week Low
  • IMAB $0.84
  • GLU $11.61
  • 52 Week High
  • IMAB $2.00
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • IMAB 43.19
  • GLU 57.11
  • Support Level
  • IMAB $1.03
  • GLU $15.40
  • Resistance Level
  • IMAB $1.10
  • GLU $15.68
  • Average True Range (ATR)
  • IMAB 0.06
  • GLU 0.31
  • MACD
  • IMAB -0.01
  • GLU 0.10
  • Stochastic Oscillator
  • IMAB 7.58
  • GLU 86.79

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: